Title |
Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy
|
---|---|
Published in |
Frontiers in immunology, January 2018
|
DOI | 10.3389/fimmu.2017.01961 |
Pubmed ID | |
Authors |
Dana P. Cook, Conny Gysemans, Chantal Mathieu |
Abstract |
Genetically modified Lactococcus lactis bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and immunogenicity. Also, containment strategies have been developed to promote further application as clinical protein-based therapeutics. Here, we review technological advancements made to enhanced the potential of L. lactis as live biofactories and discuss some examples of tolerogenic immunotherapies mediated by mucosal drug delivery via L. lactis. Additionally, we highlight their use to induce mucosal tolerance by targeted autoantigen delivery to the intestine as an approach to reverse autoimmune type 1 diabetes. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 106 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 16% |
Student > Ph. D. Student | 17 | 16% |
Student > Master | 13 | 12% |
Student > Bachelor | 12 | 11% |
Student > Doctoral Student | 7 | 7% |
Other | 12 | 11% |
Unknown | 28 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 26 | 25% |
Agricultural and Biological Sciences | 15 | 14% |
Immunology and Microbiology | 12 | 11% |
Medicine and Dentistry | 6 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Other | 9 | 8% |
Unknown | 35 | 33% |